543737-10-6

Basic information

• Product Name: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline
• Synonyms: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline;Isoquinoline, 4-(3-bromophenyl)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-
• CAS NO: 543737-10-6
• Molecular Formula: C₁₆H₁₄BrCl₂N
• Molecular Weight: 371.11
• Mol File: 543737-10-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 412.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.475±0.06 g/cm3(Predicted)
• PKA: 6.79±0.40(Predicted)
• CAS DataBase Reference: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline(543737-10-6)
• EPA Substance Registry System: 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline(543737-10-6)

Safety Data

• Hazardous Substances Data: 543737-10-6(Hazardous Substances Data)

Usage

General Description

The chemical 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline is a complex organic compound with a molecular formula of C17H16BrCl2N. It is a tetrahydroisoquinoline derivative, which is a class of compounds that has a wide range of pharmacological activities. This particular chemical is a potent dopamine D1 and D5 receptor antagonist, and it has also shown activity as a potential antipsychotic agent. Additionally, it has been studied for its potential use in the treatment of various central nervous system disorders, including schizophrenia and bipolar disorder. Its unique chemical structure and pharmacological activities make it an interesting target for further research and potential therapeutic applications.

Upstream product

• 1234366-97-2 1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanol 

Downstream Products

• 1234366-98-3 4-(3-benzylsulfanylphenyl)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinoline 
• 1234367-80-6 N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)aniline 
• 1870821-29-6 (4S)-4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract